Organo-ID
Founded 2020 · 7 employees on LinkedIn · 1 known investors
Organo-ID develops iPSC-derived organoid systems, including 3D hepatocyte models, to test drugs in better-modeled biological systems for predictive diagnostics and personalized therapies. The company serves drug development and treatment applications in oncology and rare disease, operating from Turkey with a global focus.
Founders & leadership
Organo-ID was founded in 2020 by Prof. Dr. Erdal, Bugraer Aslan, and Esra Erdal.
Investors · 1
Frequently asked questions
- What does Organo-ID do?
- Organo-ID develops iPSC-derived organoid systems, including 3D hepatocyte models, to test drugs in better-modeled biological systems for predictive diagnostics and personalized therapies. The company serves drug development and treatment applications in oncology and rare disease, operating from Turkey with a global focus.
- Who founded Organo-ID?
- Organo-ID was founded by Prof. Dr. Erdal, Bugraer Aslan, Esra Erdal in 2020.
- Who are Organo-ID's investors?
- Organo-ID's investors include Idacapital.